Asset Details
Do you wish to reserve the book?
Multicentre case-control study on the association between COVID-19 vaccines and neurological disorders (COVIVAX)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Multicentre case-control study on the association between COVID-19 vaccines and neurological disorders (COVIVAX)
Do you wish to request the book?
Multicentre case-control study on the association between COVID-19 vaccines and neurological disorders (COVIVAX)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Multicentre case-control study on the association between COVID-19 vaccines and neurological disorders (COVIVAX)
2025
Overview
The COVIVAX study assessed the association between COVID-19 vaccination and the risk of common neurological disorders in a multicenter case-control design. Vaccination exposure was compared between individuals with a first diagnosis of a neurological disorder (cases) and age- and sex-matched controls. A total of 624 participants were enrolled, and after random 1:1 matching 265 cases and 265 matched controls (total 530 participants) were included in the analyses. The most frequent neurological diagnosis in cases were stroke (60.4%), multiple sclerosis (11.3%) and seizures (6.4%). The proportion of vaccinated participants was 72.1% among cases and 79.6% among controls. A protective role of vaccination on the risk of developing a new neurological disorder was detected in the unadjusted analysis (OR 0.50; 95% CI 0.29–0.86;
p
= 0.0114). After adjustment for confounders, the number of vaccination doses received was associated with a reduced risk of developing new neurological disorders for participants aged over 60 years (
p
= 0.0472; OR 0.14, 95% CI 0.03–0.68), with pre-existing comorbidities (
p
= 0.0122; OR 0.04, 95% CI 0.01–0.99) and for stroke (
p
= 0.0232; OR 0.04, 95% CI 0.02–0.97). The COVIVAX study provided no warning sign regarding an increase in the risk of developing new neurological disorders following COVID-19 vaccination of any type or doses. A potentially protective effect of multiple doses of COVID-19 vaccines against the risk of stroke in people aged over 60 needs to be confirmed by further studies.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Adult
/ Aged
/ COVID-19
/ COVID-19 - prevention & control
/ COVID-19 Vaccines - administration & dosage
/ COVID-19 Vaccines - adverse effects
/ Female
/ Humanities and Social Sciences
/ Humans
/ Male
/ Nervous System Diseases - epidemiology
/ Nervous System Diseases - etiology
/ Science
/ Seizures
/ Stroke
/ Vaccines
